BURLINGTON, Mass., Nov. 16, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will present at the Stifel 2015 Healthcare Conference on Tuesday, November 17, 2015 at 9:30 a.m. Eastern Time at the New York Palace Hotel in New York, New York.
To access the live webcast and subsequent archived recordings for the presentation, please visit the Flexion website at http://flexiontherapeutics.com/.
About Flexion Therapeutics
Flexion is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel pain therapies. The company is currently advancing a portfolio of local, injectable, non-opioid drug candidates that have the potential to provide better and more persistent analgesia compared with existing therapy. The company's lead program, Zilretta™, is an intra-articular (IA) sustained-release therapy in development for patients with moderate to severe osteoarthritis (OA) pain. In the United States, OA is the most common joint disease, affecting 27 million people of which approximately five million patients receive IA injections for OA of the knee annually. The company also has two additional product candidates, FX007, a locally administered TrkA receptor antagonist for post-operative pain, and FX005, an IA, sustained-release p38 MAP kinase inhibitor for end-stage OA patients.
CONTACTS: Investor Relations Contact David Carey Lazar Partners LTD T: 212-867-1768 email@example.com Media Relations Contact Mariann Caprino TogoRun 917.242.1087 M.Caprino@togorun.com Corporate Contact Fred Driscoll Chief Financial Officer Flexion Therapeutics, Inc. T: 781-305-7763 firstname.lastname@example.org